Depletion of Bmi-1 enhances 5-fluorouracil-induced apoptosis and autophagy in hepatocellular carcinoma cells
- Authors:
- Jing Wu
- Dong Hu
- Rongbo Zhang
-
View Affiliations
Affiliations: Department of Medical Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China
- Published online on: July 16, 2012 https://doi.org/10.3892/ol.2012.805
-
Pages:
723-726
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
5-fluorouracil (5‑FU) is one of the standard chemoradiotherapy regimens for hepatocellular carcinoma (HCC) treatment. B‑cell‑specific Moloney murine leukemia virus insertion site 1 (Bmi‑1) has been demonstrated to regulate proliferation. Additionally, Bmi‑1 overexpression has been identified in HCC cell lines and correlates with the advanced invasive stage of tumor progression and poor prognosis. In this study, we examined the effects of 5‑FU treatment on cell growth in HCC cells with or without Bmi‑1 depletion. The IC50 values of 5‑FU were significantly decreased to a greater extent in cells with Bmi‑1 knockdown. Depletion of Bmi‑1 increased sensitivity of the cells to 5‑FU and increased apoptosis. Knockdown of endogenous Bmi‑1 led to a substantial reduction in the levels of phospho‑AKT and Bcl‑2 with a concomitant increase in the levels of Bax. Additionally, 5‑FU induced the conversion/turnover of microtubule-associated protein 1 light chain 3 (LC3). Knockdown of endogenous Bmi‑1 led to an increase in the levels of Beclin‑1 and the accumulation of LC3‑II. Together, these findings reveal that Bmi‑1 depletion enhanced the chemosensitivity of HCC cells by inducing apoptosis and autophagy, which is associated with the PI3K/AKT and Bcl‑2/Beclin‑1 pathways.
View References
|
1.
|
H NaganoTreatment of advanced
hepatocellular carcinoma: intraarterial infusion chemotherapy
combined with interferonOncology78Suppl
1142147201010.1159/000315243
|
|
2.
|
JM LIovetJ BruixMolecular targeted
therapies in hepatocellular
carcinomaHepatology4813121327200810.1002/hep.2250618821591
|
|
3.
|
M BoulinS GuiuB ChauffertS AhoJP CercueilF
GhiringhelliD KrauseP FagnoniP HillonL BedenneB GuiuScreening of
anticancer drugs for chemoembolization of hepatocellular
carcinomaAnticancer
Drugs22741748201110.1097/CAD.0b013e328346a0c521487286
|
|
4.
|
Y HauptWS AlexanderG BarriSP KlinkenJM
AdamsNovel zinc finger gene implicated as myc collaborator by
retrovirally accelerated lymphomagenesis in E mu-myc transgenic
miceCell65753763199110.1016/0092-8674(91)90383-A1904009
|
|
5.
|
M van LohuizenS VerbeekB ScheijenE
WientjensH van der GuldenA BernsIdentification of cooperating
oncogenes in E mu-myc transgenic mice by provirus
taggingCell6573775219911904008
|
|
6.
|
ME Valk-LingbeekSW BruggemanM van
LohuizenStem cells and cancer; the polycomb
connectionCell118409418200410.1016/j.cell.2004.08.00515315754
|
|
7.
|
MJ GunsterFM RaaphorstKM HamerJL den
BlaauwenE FieretCJ MeiierAP OtteDifferential expression of human
polycomb group proteins in various tissues and cell typesJ Cell
Biochem Suppl36129143200110.1002/jcb.109311455578
|
|
8.
|
H WangK PanHK ZhangDS WengJ ZhouJJ LiW
HuangHF SongMS ChenJC XiaIncreased polycomb-group oncogene Bmi-1
expression correlates with poor prognosis in hepatocellular
carcinomaJ Cancer Res Clin
Oncol134535541200810.1007/s00432-007-0316-817917742
|
|
9.
|
L LiuLG AndrewsTO TollefsbolLoss of the
human polycomb group protein BMI1 promotes cancer-specific cell
deathOncogene2543704375200610.1038/sj.onc.120945416501599
|
|
10.
|
J WuD HuG YangJ ZhouC YangY GaoZ
ZhuDown-regulation of Bmi-1 cooperates with artemisinin on growth
inhibition of nasopharyngeal carcinoma cellsJ Cell
Biochem11219381948201110.1002/jcb.2311421445878
|
|
11.
|
JE ChipukDR GreenHow do Bcl-2 proteins
induce mitochondrial outer membrane permeabilization?Trends Cell
Biol18157164200810.1016/j.tcb.2008.01.00718314333
|
|
12.
|
S WhittakerR MaraisAX ZhuThe role of
signaling pathways in the development and treatment of
hepatocellular
carcinomaOncogene2949895005201010.1038/onc.2010.23620639898
|
|
13.
|
YL ChenPY LawHH LohInhibition of PI3K/Akt
signaling: an emerging paradigm for targeted cancer therapyCurr Med
Chem Anticancer
Agents5575589200510.2174/15680110577457464916305480
|
|
14.
|
JM GumpA ThorburnAutophagy and apoptosis:
what is the connection?Trends Cell
Biol21387392201110.1016/j.tcb.2011.03.00721561772
|
|
15.
|
F ZhouY YangD XingBcl-2 and Bcl-xl play
important roles in the crosstalk between autophagy and
apoptosisFEBS
J278403413201110.1111/j.1742-4658.2010.07965.x21182587
|
